CN1419124A - 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 - Google Patents
一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 Download PDFInfo
- Publication number
- CN1419124A CN1419124A CN 02157379 CN02157379A CN1419124A CN 1419124 A CN1419124 A CN 1419124A CN 02157379 CN02157379 CN 02157379 CN 02157379 A CN02157379 A CN 02157379A CN 1419124 A CN1419124 A CN 1419124A
- Authority
- CN
- China
- Prior art keywords
- water
- red sage
- ginsenoside
- sage root
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000007164 Salvia officinalis Species 0.000 title claims abstract description 220
- 235000005412 red sage Nutrition 0.000 title claims abstract description 154
- 150000001875 compounds Chemical class 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims description 31
- 201000010099 disease Diseases 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000003908 quality control method Methods 0.000 claims abstract description 20
- 229960003371 protocatechualdehyde Drugs 0.000 claims abstract description 18
- 230000003203 everyday effect Effects 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 157
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 99
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 99
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 99
- 229940116229 borneol Drugs 0.000 claims description 99
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 99
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 94
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 60
- 239000006210 lotion Substances 0.000 claims description 45
- 238000005406 washing Methods 0.000 claims description 45
- 229940089161 ginsenoside Drugs 0.000 claims description 40
- 229930182494 ginsenoside Natural products 0.000 claims description 40
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 23
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 21
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 21
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 21
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims description 17
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 16
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 14
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims description 13
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 10
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 229930183118 Tanshinone Natural products 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 8
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 230000005526 G1 to G0 transition Effects 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- IFXGUZKGCKIMQN-UHFFFAOYSA-N oxalonitrile;hydrate Chemical compound O.N#CC#N IFXGUZKGCKIMQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- ZMMKVDBZTXUHFO-DDWIOCJRSA-M sodium;(2r)-3-(3,4-dihydroxyphenyl)-2-hydroxypropanoate Chemical compound [Na+].[O-]C(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 ZMMKVDBZTXUHFO-DDWIOCJRSA-M 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 170
- 239000003814 drug Substances 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 229930182478 glucoside Natural products 0.000 abstract 1
- 150000008131 glucosides Chemical class 0.000 abstract 1
- 239000000344 soap Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 345
- 244000131316 Panax pseudoginseng Species 0.000 description 113
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 113
- 239000012141 concentrate Substances 0.000 description 71
- 235000017276 Salvia Nutrition 0.000 description 65
- 239000000843 powder Substances 0.000 description 57
- 238000001035 drying Methods 0.000 description 56
- 239000007788 liquid Substances 0.000 description 53
- 239000000203 mixture Substances 0.000 description 45
- 239000011347 resin Substances 0.000 description 42
- 229920005989 resin Polymers 0.000 description 42
- 238000010828 elution Methods 0.000 description 41
- 239000006228 supernatant Substances 0.000 description 40
- 239000006187 pill Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 239000000463 material Substances 0.000 description 30
- 239000002775 capsule Substances 0.000 description 25
- 238000007670 refining Methods 0.000 description 23
- 239000002245 particle Substances 0.000 description 21
- 238000000605 extraction Methods 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 18
- 244000132619 red sage Species 0.000 description 18
- 238000001556 precipitation Methods 0.000 description 17
- 239000007921 spray Substances 0.000 description 17
- 238000010992 reflux Methods 0.000 description 15
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 102000011759 adducin Human genes 0.000 description 9
- 108010076723 adducin Proteins 0.000 description 9
- 239000009524 danshen dripping Substances 0.000 description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 208000031225 myocardial ischemia Diseases 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 229920002545 silicone oil Polymers 0.000 description 8
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 239000002826 coolant Substances 0.000 description 7
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 7
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000009413 insulation Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000011122 softwood Substances 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229930189533 tanshinol Natural products 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000008118 PEG 6000 Substances 0.000 description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- 206010041956 Stasis syndrome Diseases 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 208000005634 blind loop syndrome Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 229930004069 diterpene Natural products 0.000 description 4
- 125000000567 diterpene group Chemical group 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- -1 Rosmarinic acid methyl esters Chemical class 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000003822 preparative gas chromatography Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 死亡时间(分) |
空白对照组模型对照组复方丹参制剂复方丹参制剂复方丹参制剂 | 31.8±8.63***16.0±3.6522.2±5.67**20.6±4.12*19.3±4.06 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021573794A CN100412545C (zh) | 2002-12-23 | 2002-12-23 | 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021573794A CN100412545C (zh) | 2002-12-23 | 2002-12-23 | 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1419124A true CN1419124A (zh) | 2003-05-21 |
CN100412545C CN100412545C (zh) | 2008-08-20 |
Family
ID=4752955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021573794A Expired - Lifetime CN100412545C (zh) | 2002-12-23 | 2002-12-23 | 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100412545C (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005088295A1 (fr) * | 2004-03-17 | 2005-09-22 | Tianjin Tasly Pharmaceutical Co., Ltd. | Procede de controle de qualite destine aux pilules a avaler composees de danshen |
CN1327217C (zh) * | 2004-05-26 | 2007-07-18 | 江西江中药业股份有限公司 | 健胃消食片的质量控制方法 |
CN1333248C (zh) * | 2003-07-14 | 2007-08-22 | 北京中医药大学 | 栀子药材和栀子半成品指纹图谱检测的质量控制方法 |
CN100339706C (zh) * | 2003-06-19 | 2007-09-26 | 北京中医药大学 | 一种由栀子和三七制备的注射液的质量控制方法 |
CN100381813C (zh) * | 2004-03-16 | 2008-04-16 | 天津天士力制药股份有限公司 | 复方丹参滴丸质量控制方法 |
CN100381817C (zh) * | 2004-03-17 | 2008-04-16 | 天津天士力制药股份有限公司 | 一种复方丹参滴丸质量控制方法 |
CN100390538C (zh) * | 2005-06-20 | 2008-05-28 | 中国医学科学院药用植物研究所 | 一种达玛烷型四环三萜皂苷的检测方法 |
CN100458421C (zh) * | 2005-09-28 | 2009-02-04 | 沈百华 | 林下参与栽培人参的微量化学鉴别方法 |
CN1919251B (zh) * | 2005-08-24 | 2010-11-03 | 天津天士力制药股份有限公司 | 治疗心血管疾病的中药组合物 |
CN1919240B (zh) * | 2005-08-24 | 2011-02-16 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药 |
CN1919243B (zh) * | 2005-08-24 | 2011-03-23 | 天津天士力制药股份有限公司 | 一种治疗心脑血管疾病的中药组合物 |
CN101574359B (zh) * | 2008-05-09 | 2011-09-14 | 昆明制药集团股份有限公司 | 一种治疗心脑血管疾病的药物组合物 |
CN102309543A (zh) * | 2010-06-30 | 2012-01-11 | 广东环球制药有限公司 | 复方丹参浓缩制剂及其制备、检测方法 |
CN101607954B (zh) * | 2008-06-18 | 2012-10-24 | 复旦大学 | 一种丹参素衍生物及其制备方法和在药学上的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1074121A (zh) * | 1992-10-24 | 1993-07-14 | 广西卫生学校附属药厂 | 一种治疗冠心病中药片剂的生产方法 |
CN1144673A (zh) * | 1995-09-04 | 1997-03-12 | 张相国 | 丹参及其组方复方丹参粉针剂和制备方法 |
CN1141575C (zh) * | 2001-06-29 | 2004-03-10 | 天津市金士力药物研究开发有限公司 | 一种丹参药材的鉴别方法 |
-
2002
- 2002-12-23 CN CNB021573794A patent/CN100412545C/zh not_active Expired - Lifetime
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100339706C (zh) * | 2003-06-19 | 2007-09-26 | 北京中医药大学 | 一种由栀子和三七制备的注射液的质量控制方法 |
CN1333248C (zh) * | 2003-07-14 | 2007-08-22 | 北京中医药大学 | 栀子药材和栀子半成品指纹图谱检测的质量控制方法 |
CN100381813C (zh) * | 2004-03-16 | 2008-04-16 | 天津天士力制药股份有限公司 | 复方丹参滴丸质量控制方法 |
WO2005088295A1 (fr) * | 2004-03-17 | 2005-09-22 | Tianjin Tasly Pharmaceutical Co., Ltd. | Procede de controle de qualite destine aux pilules a avaler composees de danshen |
CN100381817C (zh) * | 2004-03-17 | 2008-04-16 | 天津天士力制药股份有限公司 | 一种复方丹参滴丸质量控制方法 |
CN1327217C (zh) * | 2004-05-26 | 2007-07-18 | 江西江中药业股份有限公司 | 健胃消食片的质量控制方法 |
CN100390538C (zh) * | 2005-06-20 | 2008-05-28 | 中国医学科学院药用植物研究所 | 一种达玛烷型四环三萜皂苷的检测方法 |
CN1919251B (zh) * | 2005-08-24 | 2010-11-03 | 天津天士力制药股份有限公司 | 治疗心血管疾病的中药组合物 |
CN1919240B (zh) * | 2005-08-24 | 2011-02-16 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药 |
CN1919243B (zh) * | 2005-08-24 | 2011-03-23 | 天津天士力制药股份有限公司 | 一种治疗心脑血管疾病的中药组合物 |
CN100458421C (zh) * | 2005-09-28 | 2009-02-04 | 沈百华 | 林下参与栽培人参的微量化学鉴别方法 |
CN101574359B (zh) * | 2008-05-09 | 2011-09-14 | 昆明制药集团股份有限公司 | 一种治疗心脑血管疾病的药物组合物 |
CN101607954B (zh) * | 2008-06-18 | 2012-10-24 | 复旦大学 | 一种丹参素衍生物及其制备方法和在药学上的应用 |
CN102309543A (zh) * | 2010-06-30 | 2012-01-11 | 广东环球制药有限公司 | 复方丹参浓缩制剂及其制备、检测方法 |
CN102309543B (zh) * | 2010-06-30 | 2014-01-01 | 广东环球制药有限公司 | 复方丹参浓缩制剂及其制备、检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100412545C (zh) | 2008-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101612362B (zh) | 一种调节血脂、防治心脑血管疾病复方制剂及其制备方法 | |
CN1669573A (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 | |
CN1470255A (zh) | 自丹参三七中提取的制备物及其复方制备方法和医疗用途 | |
CN1419124A (zh) | 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 | |
CN103083557A (zh) | 具有降血压和降血脂作用的中药组合物 | |
CN1943618A (zh) | 丹参有效部位标准提取物及其制备方法和应用 | |
CN1267111C (zh) | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 | |
CN1296063C (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN1742949A (zh) | 一种具有降压、降脂、定眩、定风作用的中药组合物及其制备方法和其用途 | |
CN1615958A (zh) | 用于治疗中风和胸痹的中药制剂及其制备方法 | |
CN1319519C (zh) | 一种治疗心脑血管疾病的复方丹参喷雾剂 | |
CN1319521C (zh) | 一种治疗心脑血管疾病的复方丹参颗粒 | |
CN1309397C (zh) | 一种治疗心脑血管疾病的复方丹参胶囊及其制备方法 | |
CN1422664A (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN1320881C (zh) | 一种治疗急慢性肝炎的滴丸 | |
CN107913277A (zh) | 丹参酮抗尿酸性肾病的用途 | |
CN1582952A (zh) | 积雪草总苷在制备防治心、脑血管疾病药物中的用途 | |
CN1903238A (zh) | 一种中药提取物、制剂及其制备方法与用途 | |
CN1876097A (zh) | 治疗妇女更年期综合症改进的中药胶囊 | |
CN1762362A (zh) | 一种治疗心脑血管疾病的丹参成份药物组合物及其应用 | |
CN1899388A (zh) | 一种双丹软胶囊及其制备方法 | |
CN1225270C (zh) | 一种治疗动脉粥样硬化的药物及其制备方法 | |
CN1857446A (zh) | 含有麝香的药物组合物 | |
CN1299670C (zh) | 消栓软胶囊及其制备方法 | |
CN1857447A (zh) | 含有冰片、麝香的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACY CO., LTD. Free format text: FORMER OWNER: BEIJING CAIRUI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20100420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: BEIJING CAIRUI MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER NAME: BEIJING CAIRUI MEDICINE CO., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100029 ROOM 601, WEITE OFFICE BUILDING, NO.A11,NORTH 3RD RING EAST ROAD, CHAOYANG DISTRICT, BEIJING CITY TO: 300410 TIANSHILI MODERM CHINESE MEDICINE CITY, NO.2, PUJIHE EAST ROAD, BEICHEN DISTRICT, TIANJIN CITY |
|
CP03 | Change of name, title or address |
Address after: 100029, Witt, office building 11, 601 North Third Ring Road, Beijing, Chaoyang District Patentee after: BEIJING CAIRUI MEDICAL TECHNOLOGY Co.,Ltd. Address before: 100029, Beijing, Chaoyang District cherry garden, 19 floor, 507 Patentee before: BEIJING CAIRUI MEDICINE Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100420 Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 100029, Witt, office building 11, 601 North Third Ring Road, Beijing, Chaoyang District Patentee before: BEIJING CAIRUI MEDICAL TECHNOLOGY Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CX01 | Expiry of patent term |
Granted publication date: 20080820 |
|
CX01 | Expiry of patent term |